Related Experiment Video
Updated: Oct 21, 2025
Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
[Intracerebral haemorrhage twelve days after vaccination with ChAdOx1 nCoV-19]
Signe Amalie Wolthers1, Jakob Stenberg, Henning Bay Nielsen
1s.a.wolthers@gmail.com.
Insights
A rare condition called vaccine-induced immune thrombotic thrombocytopenia (VITT) has been linked to COVID-19 adenovirus vector vaccines. This case report highlights VITT presenting as fatal intracerebral hemorrhage post-vaccination.
Area of Science:
- Immunology
- Neurology
- Vaccinology
Background:
- The COVID-19 pandemic spurred rapid vaccine development, including adenovirus vector vaccines.
- Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious adverse event associated with these vaccines.
Observation:
- This case report details a previously healthy male who developed severe thrombocytopenia.
- The patient experienced a fatal intracerebral hemorrhage within the typical timeframe for VITT post-vaccination.
Findings:
- The clinical presentation of headache, abdominal pain, thrombosis, or hemorrhage along with thrombocytopenia warrants suspicion for VITT.
- Adenovirus vector vaccines, specifically ChAdOx1 nCoV-19 (Vaxzevria) and Ad26.COV2-S (Janssen), are implicated in VITT.
Implications:
- Early recognition and diagnosis of VITT are crucial for patient management.
- Understanding the mechanisms and risk factors for VITT is essential for vaccine safety monitoring.
- This case underscores the importance of vigilance for rare vaccine side effects.
Abstract:
The COVID-19-pandemic has had a huge impact on health and economics all over the world resulting in widespread vaccine development. Vaccine-induced immune thrombotic thrombocytropenia has been described, suggesting a link between the two adeno-vector vaccines ChAdOx1 nCoV-19 (Vaxzevria from AstraZeneca) and Ad26.COV2-S (Janssen from Johnson and Johnson). This rare clinical condition should be suspected in patients with headache, abdominal pain, suspected thrombosis or hemorrhage and thrombocytopenia within 3-30-day post vaccine. In this case report a previously healthy man had thrombocytopenia with fatal intracerebral haemorrhage which was suspected to be related to vaccine.
